Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
This article reports on the lived experience of Medtronic advanced hybrid closed-loop (AHCL) in comparison to first generation hybrid closed-loop (HCL) in a randomized, open-label, two-period crossover trial. Patient-reported outcome (PROs) measures were administered before randomization and at the end of each study period in 113 adolescents and young adults with type 1 diabetes. Glucose monitoring satisfaction subscales for emotional burden and behavioral burden improved significantly ( P < 0.01) over time with use of AHCL versus HCL and co-occurred with glycemic improvements (reduced percent time above 180 mg/dL during the day and no change in % time less than 54 mg/dL across 24 h) and greater time in Auto Mode. PROs, including distress, technology attitudes, and hypoglycemia confidence, were not different. AHCL use was associated with improved glucose monitoring satisfaction. Satisfaction was greater in those participants who had more appreciable glycemic benefit and stayed in Auto Mode more often. Clinical Trial Registration number: NCT03040414.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Self-citationFisher, L., Hessler, D., Polonsky, W. H., Masharani, U., Guzman, S., Bowyer, V., Strycker, L., Ahmann, A., Basina, M., Blumer, I., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0391 · Cited by 104
Cited by
Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C., Evans, M., Ré, R., de Portu, S., Vorrink, L., Shin, J., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00212-1 · Cited by 204
Matejko, B., Juza, A., Kieć-Wilk, B., Cyranka, K., Krzyżowska, S., Chen, X., Cohen, O., Da Silva, J., Malecki, M. T., & Klupa, T. (2022) · Diabetes Care · doi:10.2337/dc22-0470 · Cited by 72
“In these randomized controlled trials as well as clinical experiences the effectiveness of the MiniMed 780G system was evaluated predominantly in individuals who had previously used diabetes technologies, either insulin pumps (continuous subcutaneous insulin infusion [CSII]) or CGM systems, with or without various lev…”
BackgroundIdentifying the deficiencies of currently available CGM to improve uptake and benefit
Barnard‐Kelly, K. D., Martínez‐Brocca, M. A., Glatzer, T., & Oliver, N. (2024) · Diabetic Medicine · doi:10.1111/dme.15338 · Cited by 37
“18 Undoubtedly, such systems will automate, to differing degrees, the response to CGM data by the user and potentially reduce some of the associated burdens.”
Monroy, G., Picón-César, M. J., García-Alemán, J., Tinahones, F. J., & Martínez-Montoro, J. I. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0522 · Cited by 17
Amigó, J., Ortiz-Zúñiga, Á., de Urbina, A. M. O., Sánchez, M., Dos-Santos, M., Abad, M., Cuadra, F., Simó, R., Hernández, C., & Simó-Servat, O. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110730 · Cited by 15
Metadata
- Authors
- Hood, K. K., Laffel, L. M., Danne, T., Nimri, R., Weinzimer, S. A., Sibayan, J., Bailey, R. J., Schatz, D., Bratina, N., Bello, R., Punel, A., Calhoun, P., Beck, R. W., Bergenstal, R. M., Phillip, M., & for the FLAIR Study Group
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2021-12-01
- Volume
- 23
- Issue
- 12
- Pages
- 857-861
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3177735841
- Cited by
- 57
- References
- 2
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.